● Recruiting

To Evaluate the Efficacy, Safety and Population Pharmacokinetics of GST-HG141 in Patients With Chronic Hepatitis B (CHB) Who Have an Inadequate Response to Antiviral Drug Treatment

Condition: Chronic Hepatitis b · Sponsor: Fujian Akeylink Biotechnology Co., Ltd.

PhasePhase 3

Planned participants526

Who can joinAll sexes, 18 Years to 70 Years

Healthy volunteersNo

About this study

This study is a multicenter, randomized, double-blind, placebo-controlled phase III clinical trial, aiming to evaluate the efficacy and safety of GST-HG141 in patients with chronic hepatitis B who have an inadequate response to antiviral drug treatment.

This description comes directly from the study's public registry record.

Talk to the study team

Yan wenhao, MD · 17390087876 · yanwenhao@akeylink.cn

Always discuss trial participation with your own doctor first.

Locations (1)

Shulan(Hangzhou) Hospital

Hangzhou, Zhejiang, China

Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07090759